Plain-English translation of NCT03926130 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn's disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested , a new medication designed to help people with moderate to severe Crohn's disease. Researchers studied whether the medication was safe and actually worked better than a placebo (dummy treatment) or another existing medication. About 1,158 people participated in this study, which compared different doses of the new treatment.
Many people with Crohn's disease don't respond well enough to current treatments, or they stop working over time. This medication was being tested to see if it could offer a better option for patients whose disease remains active despite other therapies.
Participants were randomly assigned to receive either a placebo, the new medication at different doses, or an existing Crohn's disease medication. Most received intravenous (IV) infusions every 4 weeks for the first few doses, then switched to injections under the skin. The trial involved regular clinic visits over several months so researchers could monitor how well the treatment worked and check for any side effects.
AI-generated summary from trial data · Sep 4, 2026 · Not medical advice
United States